Talquetamab in Pts with Relapsed/Refractory Multiple Myeloma: Phase 1/2 Results from MonumenTAL-1 Published 2023-01-23 Download video MP4 360p Recommendations 17:55 Talquetamab | Therapies on the horizon 1:02:01 Top Myeloma Research Presented at ASCO & EHA 2024 1:00:10 Diagnosis and Management of Headache 09:33 Talquetamab | Ajai Chari, MD | ASH 2022 59:50 IMWG Conference Series 2024: Making Sense of Treatment 1:02:46 To Grow New Pancreatic Beta Cells... Put the Old Ones to Work 1:12:12 Scott Thornbury at The New School 06:02 Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R multiple myeloma 03:44 What should myeloma patients know about talquetamab? 1:28:14 Darwin, Diet, Disease, and Dollars: How the Sugar in Processed Foods Has Changed Society 35:45 MicroRNAs in the Development and Treatment of Cancer | Memorial Sloan Kettering 36:58 What You Need to Know about Non-Hodgkin's Lymphoma: Presentation 05:12 What is BCMA? 02:35 Are four drug combinations recommended for older transplant in eligible myeloma patients? 58:43 Multiple Sclerosis in 2022 1:00:58 Missing Microbes with Dr Martin Blaser 11:42 Stem Cells In Chronic Diseases | Roberta Shapiro | TEDxBeaconStreet 1:04:21 BCS - Episode 20: Thriving Beyond Non-Hodgkin's Lymphoma Similar videos 08:43 Results from MonumenTAL-1: First-in-Human Study of Talquetamab in Pts with RR Multiple Myeloma 10:02 ASH 2022: Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Re... 15:21 Updates on Efficacy/Safety Results from MonumenTAL-1 (Talquetamab) in RRMM patients 05:31 Phase 2 Results: Talquetamab, a GPRC5DxCD3 BsAb, shows potential for relapsed refractory MM 06:36 Updated results of a phase 1, first-in-human study of talquetamab in relapsed refractory MM 10:11 MonumenTAL-1: talquetamab in R/R multiple myeloma 02:47 MonumenTAL-1: updated data on talquetamab in R/R myeloma 04:57 ASH 2022: Talquetamab Showing Promise in Multiple Myeloma Clinical Trial 03:44 ASH 2021: New Bispecific Antibody, Talquetamab, To Treat Multiple Myeloma 06:10 Updated Phase1B Results for Talquetamab in Combination with Daratumumab 03:53 Efficacy of Reduced Dosing of Talquetamab in Relapsed Refractory Myeloma | Ajai Chari, MD | ASH 2023 07:43 ASH 2023 | Relapsed and refractory myeloma: Phase 1/2 MonumenTAL 1 Study 02:47 Talquetamab + Daratumumab Is Well Tolerated in Relapsed/Refractory Multiple Myeloma Patients 06:58 Phase 1 Study of the GPRC5DxCD3 Bispecific Talquetamab in Patients with RR Multiple Myeloma 03:54 Safety and efficacy of the bispecific antibody talquetamab in relapsed/refractory multiple myeloma 06:31 Real-World Results from Talquetamab and Bispecific Antibodies | Carolina Schinke, MD | ASH 2023 01:44 TRIMM-2: talquetamab + daratumumab in patients with R/R multiple myeloma More results